Skip to main content
SpringerLink
Log in

Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel

  • case report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

As the prognosis of enteropathy-associated T‑cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody–drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T‑cell lymphoma that affected the jejunum. Standard chemotherapy with CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinued owing to another condition that required surgery, upon which the patient relapsed. However, resumption of brentuximab vedotin therapy restored partial remission within 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Okada M, Maeda K, Suzumiya J, et al. Primary colorectal T‑cell lymphoma. J Gastroenterol. 2003;38(3):376–84.

    Article  PubMed  Google Scholar 

  2. Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica. 1997;82(3):305–8.

    CAS  PubMed  Google Scholar 

  3. Swerdlow SH, Campo E, Harris NL. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  4. Sieniawski MK, Lennard AL. Enteropathy-associated T‑cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6(4):231–40.

    Article  PubMed  Google Scholar 

  5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T‑cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–70.

    Article  CAS  PubMed  Google Scholar 

  7. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T‑cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8.

    Article  PubMed  Google Scholar 

  8. Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5.

    Article  CAS  PubMed  Google Scholar 

  9. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T‑cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84.

    Article  CAS  PubMed  Google Scholar 

  10. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T‑cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803.

    Article  CAS  PubMed  Google Scholar 

  11. Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T‑cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32.

    Article  CAS  PubMed  Google Scholar 

  12. d’Amore F, Relander T, Lauritzsen GF, et al. Upfront autologous stem-cell transplantation in peripheral T‑cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  PubMed  Google Scholar 

  13. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T‑cell lymphoma: clinical and histological findings from the International Peripheral T‑Cell Lymphoma Project. Blood. 2011;118(1):148–55.

    Article  CAS  PubMed  Google Scholar 

  14. van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4:458–65.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T‑cell lymphoma. J Natl Compr Canc Netw. 2013;11:137–40.

    Article  PubMed  Google Scholar 

  16. Zelenetz AD, Abramson JS, Advani RH. et al. NCCN Clinical Practice Guidelines in oncology for Non-Hodgkin’s lymphomas. Version 1.2013 2013. NCCN.org. Accessed 16 January 2013.

    Google Scholar 

  17. Grigg-Gutierrez NM, Estremera-Marcial R, Caceres WW, Toro DH. Primary enteropathy-associated T‑cell lymphoma type 2: an emerging entity? Cancer Control. 2015;22(2):242–7.

    PubMed  Google Scholar 

  18. Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33(2):231–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The author thanks Judith Moser for editorial support.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital Vöcklabruck, Dr.-Wilhelm-Bock-Straße 1, 4840, Vöcklabruck, Austria

    Ferdinand Haslbauer MD

Authors
  1. Ferdinand Haslbauer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferdinand Haslbauer MD.

Ethics declarations

Conflict of interest

F. Haslbauer declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haslbauer, F. Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel. memo 10, 111–114 (2017). https://doi.org/10.1007/s12254-017-0312-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-017-0312-x

Keywords

Search

Navigation